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Abstract 
Objective 
Diabetes increases cardiovascular risk and reduces pharmacodynamic response to some oral 
antiplatelet drugs. This study aimed to determine whether ticagrelor 60 mg twice daily (bid) 
provided potent and consistent platelet inhibition in patients with vs. without diabetes in the 
PEGASUS-TIMI 54 platelet function substudy. 
Methods 
Out of 180 patients studied, 58 patients were randomized to and had received at least 4 weeks 
of ticagrelor 60 mg bid, with 20 (34%) having diabetes, 58 patients received ticagrelor 90 mg 
bid, with 12 (21%) having diabetes, and 64 patients received placebo, with 18 (28%) having 
diabetes. Blood was sampled pre- and 2 hours post-maintenance dose. 
Results 
In patients treated with ticagrelor 60 mg bid, on-treatment platelet reactivity to ADP, as 
determined by light transmission aggregometry (LTA), VerifyNow and VASP, was similar in 
patients with vs. without diabetes (LTA post-dose, ADP 20 µM: 29 ± 14 vs. 34 ± 10%, 
respectively; P = 0.19). A consistent inhibitory effect of ticagrelor 60 mg bid was observed 
pre- and post-dose regardless of diabetes status, even in insulin-treated patients. Patients with 
diabetes did not have an increased incidence of high platelet reactivity in either ticagrelor 
group. Platelet reactivity was similar in patients with diabetes treated with ticagrelor 60 mg 
vs. 90 mg bid. Pharmacokinetics of ticagrelor were not affected by diabetes status. 
Conclusions 
Ticagrelor 60 mg bid is equally effective at reducing platelet reactivity in patients with and 
without diabetes, yielding a consistently high level of platelet inhibition regardless of 
diabetes status. 
Trial registration number: NCT01225562 
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What is already known about this subject? 
Patients with diabetes have both a reduced pharmacodynamic response to some antiplatelet 
medications and an increased risk of atherothrombotic events. 
It has not previously been demonstrated whether the 60 mg twice-daily dose of ticagrelor is 
sufficient to achieve satisfactory platelet inhibition in patients with diabetes. 
What does this study add? 
A new 60 mg twice-daily dose of ticagrelor provides potent and consistent platelet inhibition 
in patients with diabetes, similar to the level seen in patients without diabetes. 
These findings provide insight into the similar effect of ticagrelor 60 mg and 90 mg twice 
daily on clinical outcomes in patients with diabetes in the PEGASUS TIMI-54 study.   
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Introduction 
Patients with diabetes are at increased risk of coronary artery disease and their prognosis 
following acute coronary syndromes (ACS) remains worse than patients without diabetes (1). 
Diabetes is associated with increased platelet turnover and other platelet abnormalities, which 
increases the risk of thrombosis and highlights the importance of optimizing antithrombotic 
therapy in patients with diabetes (2).   
It is well established that dual antiplatelet therapy, consisting of aspirin and a platelet P2Y12 
inhibitor, reduces the risk of further adverse cardiovascular events in the year following ACS 
(3). More recently, long-term treatment with dual antiplatelet therapy, initiated or continued 
from 1-3 years after ACS, has also been shown to reduce the risk of further myocardial 
infarction, stent thrombosis and cardiovascular death compared to aspirin alone (4,5). 
However, more intensive antiplatelet therapy also increases major bleeding (4,5). Diabetes is 
characterized by an enhanced thrombotic environment and compromised response to some 
oral antiplatelet agents (6-12), suggesting this population requires more aggressive 
antiplatelet therapy to reduce atherothrombotic risk. The challenge, however, is to 
individualize therapy to maximise cardiovascular benefit whilst minimising bleeding risk. 
Dosing of antiplatelet therapy and selection of appropriate patients are critical considerations 
for achieving the optimal balance between preventing thrombosis and causing bleeding. 
The PEGASUS TIMI-54 study tested both ticagrelor 90 mg bid (the standard maintenance 
dose used in patients presenting with ACS) and a new lower dose of ticagrelor 60 mg bid 
against placebo in low dose aspirin-treated patients 1-3 years after acute myocardial 
infarction (AMI) (4). Overall, the reduction in major adverse cardiovascular events prevented 
by ticagrelor 60 mg was similar to that observed with ticagrelor 90 mg. However, 
encouragingly, the rates of TIMI major bleeding were numerically lower in patients treated 
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with ticagrelor 60 mg compared with ticagrelor 90 mg. Interestingly, patients with diabetes 
showed higher absolute cardiovascular benefit from long-term dual antiplatelet therapy than 
patients without diabetes (13). Platelet function analysis demonstrated that ticagrelor 60 mg 
caused a similar level of platelet P2Y12 inhibition compared with ticagrelor 90 mg in the 
overall population (14). However, it has not yet been demonstrated whether this lower dose 
of ticagrelor is sufficient to reach levels of platelet inhibition that are equivalent to the 90 mg 
dose in patients with diabetes mellitus. We therefore investigated, using a number of platelet 
function tests, whether ticagrelor 60 mg and ticagrelor 90 mg caused a similar level of 
platelet P2Y12 inhibition in patients with and without diabetes. This was complemented by 
investigating the pharmacokinetic properties of ticagrelor in patients with and without 
diabetes.  
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Materials and Methods 
Study Design 
A total of 180 patients from the PEGASUS-TIMI 54 study took part in a platelet function 
substudy, which was conducted at 4 centers: 3 in the United Kingdom (Sheffield, Rotherham 
and Nottingham) and 1 in the United States (Jacksonville, Florida). Details of study design, 
methods and primary results have been published (4,14). The substudy was approved by the 
appropriate ethics committees and institutional review boards. Patient allocation was blinded 
and patients were randomized to receive placebo, ticagrelor 60 mg bid or ticagrelor 90 mg 
bid in a ratio of 1:1:1. All patients had received at least 4 weeks of study medication prior to 
assessment of platelet function. Patients took the last dose of their study medication the 
evening before their morning substudy visit. Venous blood was collected by venipuncture in 
the morning, before (pre) and 2 hours after study drug administration (post). Diabetes was 
defined as a known diagnosis at the baseline visit. 
Light transmission aggregometry 
Platelet aggregation was assessed in platelet rich plasma (PRP) using light transmission 
aggregometry (LTA) (14). A Chrono-log aggregometer (Haverton, Pennsylvania) was used to 
assess maximum platelet aggregation response to adenosine diphosphate (ADP) (5 and 20 
µM) and arachidonic acid (1 mM). In order to minimise inter-centre variability, all assays 
were performed to an established standard operating procedure (SOP). 
VerifyNow P2Y12 Assay 
Citrate-anticoagulated blood was analysed using the VerifyNow P2Y12 assay (Accumetrics 
Inc., San Diego, California) according to the manufacturer’s instructions (15). P2Y12 reaction 
units (PRU) and percent inhibition (determined from the estimated baseline response derived 
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by stimulating with thrombin receptor-activation peptide) were recorded. In order to 
minimise inter-center variability, all assays were performed to an established SOP. 
Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay 
Whole blood was processed using a VASP phosphorylation kit and flow cytometry. Platelet 
reactivity index (PRI) was determined according to the manufacturer’s instructions 
(BioCytex, Marseille, France) (15). 
Serum thromboxane B2 
Venous blood was collected into a serum separator tube (Becton Dickinson, Oxford, UK) and 
incubated at 37°C for 30 minutes, followed by centrifugation at 1,000 g for 15 minutes (14). 
Serum was then transferred to cryovials and stored at -80°C prior to analysis. An ELISA kit 
(Cayman Chemicals, Ann Arbor, Michigan) was used to measure thromboxane B2 levels. 
Determination of high platelet reactivity 
High on-treatment platelet reactivity (HPR) was determined using thresholds for each assay 
that have previously been shown to be associated with increased ischaemic risk (16). These 
thresholds are as follows: maximum LTA response to 20 µM ADP > 59%; maximum LTA 
response to 5 µM ADP > 46%; VerifyNow P2Y12 assay >208 PRU; VASP PRI > 50%; 
VerifyNow aspirin response units > 550; and maximum LTA response to arachidonic acid 
>20% (16-19). 
Pharmacokinetic studies 
Venous blood was collected into lithium heparin tubes and kept on ice before centrifugation 
at 1,500 g within 30 minutes. Plasma was immediately frozen at -20°C in a polypropylene 
tube prior to transfer to Covance Central Laboratories (Indianapolis, Indiana) for 
measurement of ticagrelor and AR-C124910XX levels (14). 
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Statistical analysis 
Continuous data are expressed as mean ± standard deviation (SD) or medians (interquartile 
range), as appropriate. Categorical data are expressed as proportions (%). Patient 
characteristics were compared using Fisher’s exact test for categorical data and continuous 
baseline characteristic data were compared using the Mann-Whitney U test. Continuous data 
were compared between patients with or without diabetes in each of the treatment groups 
using 2-way ANOVA with correction for multiple comparisons as appropriate. For the 
purposes of this post-hoc exploratory analysis, a P value < 0.05 was considered nominally 
significant. Data were analysed using R version 3.2.4 (the R Project for Statistical 
Computing). Analyses included assessment by centre to exclude significant inter-centre 
variability (Figure S14). 
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Results 
Study Population 
Fifty of the 180 patients who took part in the PEGASUS platelet function substudy had a 
baseline history of diabetes mellitus (Figure S1). The prevalence of diabetes was 18/64 
(28%), 20/58 (34%) and 12/58 (21%) in the placebo, ticagrelor 60 mg and ticagrelor 90 mg 
groups, respectively. Of patients with diabetes, 58% were treated with oral hypoglycemic 
therapy (but not insulin), 26% were treated with insulin and 16% were diet-controlled. 
Compared with patients without diabetes, patients with diabetes had significantly greater 
body mass index, higher prevalence of hypercholesterolaemia and hypertension, and a lower 
proportion of patients of Caucasian race (Table 1 and Table S2). The proportion of patients 
with a preceding non-ST-elevation MI, as opposed to an ST-elevation MI, was greater in 
patients with diabetes compared with those without diabetes (Table 1). The time interval 
between the last dose of study medication and measurement of the pre-dose sample was 
slightly greater in patients with diabetes (Table 1). 
Platelet P2Y12 Inhibition in Ticagrelor 60 mg-treated Patients with 
Diabetes 
Ticagrelor 60 mg potently and consistently inhibited P2Y12-mediated platelet reactivity both 
in patients with and without diabetes (Figures 1A-C). LTA maximum platelet aggregation 
responses to 20 µM ADP were similar in patients with and without diabetes, both pre-dose 
(34 ±14 vs. 41 ± 10 %; P = 0.15) and post-dose (29 ± 14 vs. 34 ± 10 %; P = 0.19) (Figure 
1A). As measured by the VerifyNow P2Y12 assay, PRU values were also similar in patients 
with vs. without diabetes, both pre-dose (60 ± 56 vs. 58 ± 68 PRU; P > 0.9) and post-dose (32 
± 42 vs. 27 ± 38 PRU; P > 0.9) (Figure 1B). In accordance with these findings, LTA 
maximum platelet aggregation responses to 5 µM ADP and VASP PRI values were also 
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similar in patients with vs. without diabetes (all P > 0.05) (Supplementary Figure S3 and 
Figure 1C).  
Platelet P2Y12 Inhibition in Ticagrelor 90 mg-treated Patients with 
Diabetes 
In patients treated with ticagrelor 90 mg, LTA maximum platelet aggregation responses to 20 
µM ADP were similar in patients with and without diabetes, both pre-dose (35 ± 16 vs. 36 ± 
13 %; P > 0.9) and post-dose (29 ± 14 vs. 29 ± 11 %; P > 0.9) (Figure 1A). In patients treated 
with ticagrelor 90 mg, VerifyNow pre-dose PRU values were higher in patients with vs. 
without diabetes (86 ± 57 vs. 37 ± 32 PRU; P = 0.01) (Figure 1B), but there was no 
significant difference post-dose (32 ± 21 vs. 17 ± 17 PRU; P = 0.6) (Figure 1B). Neither LTA 
maximum platelet aggregation responses to ADP (5 or 20 µM) nor VASP PRI levels 
demonstrated a difference between patients with and without diabetes treated with ticagrelor 
90 mg (Figures 1A, Supplementary Figure S3 and Figure 1C), suggesting the difference in 
VerifyNow PRU values may have been due to chance. 
Platelet P2Y12 Inhibition in Placebo-treated Patients with Diabetes 
LTA maximum platelet aggregation responses to 20 µM ADP were similar in patients with 
and without diabetes, both pre-dose (72 ± 13 vs. 74 ± 10 %; P > 0.9) and post-dose (71 ± 10 
vs. 73 ± 9 %; P > 0.9) (Figure 1A). VerifyNow PRU values were also similar in patients with 
vs. without diabetes, both pre-dose (270 ± 46 vs. 263 ± 38 PRU; P > 0.9) and post-dose (267 
± 50 vs. 267 ± 35; P > 0.9) (Figure 1B). In addition, LTA maximum platelet aggregation 
responses to 5 µM ADP and VASP PRI values were similar in patients with vs. without 
diabetes (all P > 0.05) (Supplementary Figure S3 and Figure 1C). 
High P2Y12-mediated Platelet Reactivity 
HPR, as determined by VerifyNow, VASP and LTA, was uncommon in patients treated with 
either ticagrelor 60 mg or ticagrelor 90 mg (Supplementary Table S2). Patients with diabetes 
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did not have a higher incidence of HPR than patients without diabetes in either the ticagrelor 
60 mg or ticagrelor 90 mg groups (all P > 0.05; Supplementary Table S2). 
Platelet inhibition in Patients Treated with Ticagrelor 60 mg vs. 
Ticagrelor 90 mg 
Ticagrelor 60 mg twice daily and ticagrelor 90 mg twice daily had a similar inhibitory effect, 
in both patients with and without diabetes (Figures 1 and 2), which was similar to the 
findings of the main PEGASUS platelet function sub-study (14). In patients with and without 
diabetes, the effect of ticagrelor 60 mg was not significantly lower than the effect of 
ticagrelor 90 mg according to VerifyNow, VASP, LTA and serum thromboxane B2 levels (all 
P > 0.05). 
Pharmacokinetics 
The pharmacokinetics of ticagrelor and its active metabolite AR-C124910XX were not 
affected by diabetes status (Supplementary Figure S4). Pre-dose and post-dose plasma 
ticagrelor levels were similar in those with and without diabetes in the ticagrelor 60 mg 
treatment group and there were also no differences in the ticagrelor 90 mg treatment group 
(Supplementary Figure S4). Similarly, plasma levels of AR-C124910XX were not affected 
by diabetes status (Supplementary Figure S4).  
Response to Aspirin 
Both LTA maximum aggregation response to arachidonic acid and serum thromboxane B2 
levels showed high levels of cyclooxygenase (COX)-1 inhibition by aspirin in both diabetes 
and non-diabetes patients in all treatment groups both pre-dose and post-dose of study 
medication (Supplementary Figure S5 and Figure 2). 
Diabetes Subgroups 
Ticagrelor 60 mg bid and ticagrelor 90 mg bid both had a consistently potent antiplatelet 
effect in patients with diabetes, regardless of the pharmacological management of their 
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diabetes (Supplementary Figures S6-S10). LTA, VerifyNow and VASP PRI values were not 
significantly different in diabetes patients who were diet-controlled, on oral 
pharmacotherapy, or treated with insulin compared with the non-diabetes population 
(Supplementary Figures S6-10). 
Relationship Between Level of HbA1c and Platelet Reactivity 
HbA1c values were available for patients with diabetes, but not patients without diabetes. 
There was no significant correlation between HbA1c and the results of VerifyNow PRU, 
VASP PRI, LTA and levels of serum thromboxane B2 (Figures S11-S13; Pearson correlation 
co-efficient varied between -0.27 – 0.22, all P > 0.05). This was consistent regardless of 
treatment group (Figure S12) and diabetes treatment (Figure S13). 
Relationship Between Centre and Platelet Reactivity 
Analyses of results according to centre revealed no statistically significant differences 
between centres for any of the assays (Figure S14). 
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Discussion 
Recent studies show a cardiovascular benefit of long-term administration of dual antiplatelet 
therapy in patients with MI 1-3 years previously (4). In the overall PEGASUS-TIMI 54 
platelet function substudy population, the level of platelet inhibition and cardiovascular 
benefit provided by ticagrelor 60 mg bid was similar to ticagrelor 90 mg bid (14). However, 
it has previously been shown that patients with diabetes have a reduced pharmacodynamic 
response to some types of oral antiplatelet therapy, such as aspirin and clopidogrel (7-12). 
Multiple mechanisms may contribute to these findings, which underscore the need for more 
efficacious antiplatelet therapies in patients with diabetes. We therefore investigated whether 
the 60 mg dose of ticagrelor is sufficient to provide consistent, potent platelet inhibition even 
in patients with diabetes. 
The main finding of this study was that ticagrelor 60 mg bid provides equally effective 
platelet inhibition in patients with diabetes as it does in patients without diabetes. For the first 
time, this study demonstrates that the 60 mg bid dose of ticagrelor is sufficient to provide 
consistent and potent P2Y12 inhibition in patients with diabetes. Indeed, platelet reactivity 
was similar in patients with diabetes treated with ticagrelor 60 mg and patients with diabetes 
treated with ticagrelor 90 mg. Patients with diabetes are at particularly high risk of 
subsequent adverse cardiovascular events and therefore gain more absolute benefit from 
potent P2Y12 inhibition (13). The finding that the 60 mg dose of ticagrelor is sufficient to 
potently inhibit platelet reactivity in diabetes patients is important, as this lower dose may 
provide a more favourable safety profile than the 90 mg dose (4). This is particularly 
significant for patients with diabetes, as they have an increased risk of bleeding following 
ACS (20) and our findings provide further insight into the similar effect of ticagrelor 60 mg 
and ticagrelor 90 mg on clinical outcomes in patients with diabetes in the PEGASUS-TIMI 
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54 study (13). Furthermore, these results provide reassurance for the change in dose of 
ticagrelor from 90 mg bid to 60 mg bid in the ongoing THEMIS study, which is investigating 
ticagrelor in patients with type 2 diabetes (ClinicalTrials.gov identifier NCT01991795). A 
recent study by Nardin et al. suggested a possible trend for higher platelet reactivity in 
diabetes patients treated with ticagrelor 90 mg (n=29) compared to patients without diabetes 
(21). However, a larger study by Alexopoulos et al. (22) did not show any effect of diabetes 
on the incidence of high platelet reactivity in ticagrelor 90 mg-treated patients, which is 
consistent with our findings. Although Nardin et al. demonstrated statistically significant 
correlation between the level of HbA1c and platelet reactivity in ticagrelor-treated patients, 
the degree of correlation was very weak and unlikely to be clinically meaningful (21).  
In patients treated with ticagrelor 90 mg bid, VerifyNow P2Y12 PRU pre-dose values were 
slightly higher in patients with diabetes than patients without diabetes. However, the PRU 
post-dose values and the LTA and VASP assays did not demonstrate higher platelet reactivity 
in this group of patients, suggesting that this difference in VerifyNow PRU values may have 
been due to chance, particularly since no difference was observed in the ticagrelor 60 mg 
group. 
Administration of ticagrelor 60 mg bid resulted in similar plasma levels of both ticagrelor and 
its active metabolite in patients with or without diabetes. In contrast, in a previous study, 
administration of a clopidogrel loading dose resulted in approximately 40% lower levels of 
clopidogrel active metabolite in patients with diabetes compared with those without diabetes 
(9). Combined with our results, this therefore suggests that high platelet reactivity in 
clopidogrel-treated patients with diabetes may be related to impaired metabolism of 
clopidogrel, rather than upregulated P2Y12 signaling. It is, however, unknown why diabetes 
may impair the metabolism of clopidogrel. Interestingly, there is some evidence that 
sulfonylureas, which are commonly used in the treatment of diabetes, are associated with a 
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reduced response to clopidogrel (23). Further work is therefore needed to demonstrate 
whether medications used for diabetes may interfere with the metabolism of clopidogrel. It 
has recently been shown that the 90 mg twice daily dose of ticagrelor provides more potent 
P2Y12 inhibition than prasugrel (24), although it remains to be established whether this is also 
true of the 60 mg dose. 
It is well-recognized that diabetes is associated with an increased risk of adverse 
cardiovascular events in patients with ACS (1). Patients with diabetes have upregulated 
platelet turnover and other platelet abnormalities, which may confer an increased risk of 
thrombosis (2). In addition, as seen in our study and others, patients with diabetes have a 
higher prevalence of obesity, hypertension, and hypercholesterolemia than patients without 
diabetes. Obesity, in particular, has been shown to be associated with higher platelet 
reactivity in aspirin-treated patients (25). Furthermore, diabetes is characterized by chronic 
low-grade systemic inflammation and altered fibrin clot structure, which shifts the 
homeostatic balance towards thrombosis (26). Targeting novel pathways related to these 
mechanisms therefore also has potential for reducing thrombotic risk in patients with diabetes 
in addition to the benefits already provided by platelet P2Y12 inhibition (27,28). Our study 
did not demonstrate a significant difference in levels of platelet reactivity to ADP in placebo-
treated patients with diabetes compared to patients without diabetes. The reason for this is 
unclear, but may be due to the small sample size. Alternatively, this may suggest that higher 
levels of platelet reactivity in patients with diabetes are predominantly related to response to 
antiplatelet therapy rather than inherently increased platelet reactivity. 
Limitations 
This study demonstrates the effects of ticagrelor 60 mg bid in stable patients with diabetes 
who had a prior history of MI 1-3 years previously. It has not yet been demonstrated whether 
ticagrelor 60 mg bid is capable of equivalent potent P2Y12 inhibition in other conditions, such 
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as during acute MI. Further studies are needed to investigate whether the 2 ticagrelor 
regimens also cause similar levels of adenosine uptake inhibition, as this may contribute to 
the effects of ticagrelor in vivo (29,30). Since we primarily intended to assess the impact of 
P2Y12 inhibition on COX-1 activity, we did not assess platelet function pre-aspirin 
maintenance dose and so could not compare trough levels of COX-1 inhibition in patients 
with and without diabetes. Another limitation of this study is that the number of patients with 
diabetes was relatively small, with 20 or fewer patients with diabetes in each of the treatment 
groups. 
Conclusions 
In conclusion, ticagrelor 60 mg bid is equally effective at reducing platelet reactivity in 
patients with and without diabetes, yielding a consistently high level of platelet inhibition 
regardless of diabetes status. 
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Tables 
Table 1 Baseline characteristics 
 No Diabetes  
(n = 130) 
Diabetes  
(n = 50) 
P value 
Age (median, years) 65 (60 – 68) 63 (56 – 68) 0.20 
Male sex (%) 111 (85) 40 (80) 0.37 
Caucasian race (%) 126 (97) 42 (84) 0.004 
Body Mass Index (median, 
kg/m2) 
27.8 (25.2 – 30.8) 30.5 (27.8 – 35.7) <0.001 
Body weight (kg) 85 ± 16 95 ± 23 0.003 
Prior MI diagnosis:    
NSTEMI (%) 51 (39) 32 (64) 0.004 
STEMI (%) 79 (61) 17 (34) 0.002 
Unknown (%) 0 (0) 1 (2) 0.28 
Years since MI (median, 
years) 
1.7 (1.3 – 2.2) 1.7 (1.2 – 2.1) 0.66 
Hypercholesterolaemia (%) 70 (54) 41 (82) <0.001 
Hypertension (%) 59 (45) 34 (68) 0.008 
Current smoker (%) 19 (15) 9 (18) 0.65 
Prior transient ischaemic 
attack (%) 
1 (1) 1 (2) 0.48 
Prior stroke (%) 0 (0) 0 (0) NA 
Multivessel CAD (%) 80 (62) 30 (60) 0.87 
Time since last dose of study 
medication, pre-dose (median, 
h) 
11.8 (11.1 – 12.5) 12.0 (11.6 – 14.0) 0.01 
Chronic kidney disease (%) 4 (3) 1 (2) >0.9 
Aspirin use (%) 130 (100) 50 (100) NA 
Statin use (%) 125 (96) 47 (94) 0.69 
Ace inhibitor use (%) 104 (80) 33 (66) 0.05 
Beta blocker use (%) 118 (91) 42 (84) 0.20 
Hypoglycemic therapy    
Diet-controlled (%) NA 8 (16) NA 
Oral (%) NA 29 (58) NA 
Insulin (%) NA 13 (26) NA 
Data are expressed as mean ± standard deviation or median (interquartile range). 
  
 24 
Figures 
 25 
 
 26 
 
Figure 1. Light transmission aggregometry (LTA) maximum platelet aggregation 
response to 20 µM ADP (A), VerifyNow P2Y12 Reaction Units (PRU) (B) and 
vasodilator-stimulated phosphoprotein (VASP) phosphorylation platelet reactivity 
index (PRI) (C). Pre and post maintenance dose of placebo, ticagrelor 60 mg bid or 
ticagrelor 90 mg bid. Data expressed as mean (circle) ± SD (lines). Patients with diabetes 
mellitus (DM) compared to patients without DM (No DM) in each treatment group using 2-
way ANOVA with Bonferroni correction for multiple comparisons. Dotted line indicates 
threshold value for high platelet reactivity. 
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Figure 2. Serum thromboxane B2 concentration (log transformed) pre and post 
maintenance dose of placebo, ticagrelor 60 mg bd or ticagrelor 90 mg bd. Data expressed as 
mean (circle) ± SD (lines). Patients with diabetes mellitus (DM) compared to patients without 
DM (No DM) in each treatment group using 2-way ANOVA with Bonferroni correction for 
multiple comparisons.  
 
